Kymriah™(tisagenlecleucel) in children and young adults with B-cell ALL that is refractory or relapsed at least twice



Kymriah (pronounced: Kim-RYE-ah) is the first FDA-approved CAR-T cell therapy available in the US

Usage Rights & Restrictions

This media asset is free for editorial broadcast, print, online and radio use. It is restricted for other purposes.

Request Access to Download

This file is for journalists only. Please fill out the form below to request access.

By submitting this field I verify that I am a journalist.